Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.

Medrano RFV, Hunger A, Mendonça SA, Barbuto JAM, Strauss BE.

Oncotarget. 2017 Jul 25;8(41):71249-71284. doi: 10.18632/oncotarget.19531. eCollection 2017 Sep 19. Review.

2.

Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment.

Newby BN, Mathews CE.

Front Endocrinol (Lausanne). 2017 Sep 14;8:232. doi: 10.3389/fendo.2017.00232. eCollection 2017. Review.

3.

Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers.

Moraga I, Spangler JB, Mendoza JL, Gakovic M, Wehrman TS, Krutzik P, Garcia KC.

Elife. 2017 May 12;6. pii: e22882. doi: 10.7554/eLife.22882.

4.

Chemical Reaction Network Theory elucidates sources of multistability in interferon signaling.

Otero-Muras I, Yordanov P, Stelling J.

PLoS Comput Biol. 2017 Apr 3;13(4):e1005454. doi: 10.1371/journal.pcbi.1005454. eCollection 2017 Apr.

5.

Impairment of human neural crest cell migration by prolonged exposure to interferon-beta.

Pallocca G, Nyffeler J, Dolde X, Grinberg M, Gstraunthaler G, Waldmann T, Rahnenführer J, Sachinidis A, Leist M.

Arch Toxicol. 2017 Oct;91(10):3385-3402. doi: 10.1007/s00204-017-1966-1. Epub 2017 Apr 1.

6.

The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity.

Mendoza JL, Schneider WM, Hoffmann HH, Vercauteren K, Jude KM, Xiong A, Moraga I, Horton TM, Glenn JS, de Jong YP, Rice CM, Garcia KC.

Immunity. 2017 Mar 21;46(3):379-392. doi: 10.1016/j.immuni.2017.02.017.

PMID:
28329704
7.

The molecular basis for differential type I interferon signaling.

Schreiber G.

J Biol Chem. 2017 May 5;292(18):7285-7294. doi: 10.1074/jbc.R116.774562. Epub 2017 Mar 13. Review.

PMID:
28289098
8.

A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon.

Zhang KJ, Yin XF, Yang YQ, Li HL, Xu YN, Chen LY, Liu XJ, Yuan SJ, Fang XL, Xiao J, Wu S, Xu HN, Chu L, Katlinski KV, Katlinskaya YV, Guo RB, Wei GW, Wang DC, Liu XY, Fuchs SY.

Clin Cancer Res. 2017 Apr 15;23(8):2038-2049. doi: 10.1158/1078-0432.CCR-16-1386. Epub 2016 Sep 28.

9.

Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases.

de Jong TD, Vosslamber S, Mantel E, de Ridder S, Wesseling JG, van der Pouw Kraan TC, Leurs C, Hegen H, Deisenhammer F, Killestein J, Lundberg IE, Vencovsky J, Nurmohamed MT, van Schaardenburg D, Bultink IE, Voskuyl AE, Pegtel DM, van der Laken CJ, Bijlsma JW, Verweij CL.

Arthritis Res Ther. 2016 Feb 17;18:49. doi: 10.1186/s13075-016-0946-9.

10.

The hematopoietic regulator, ELF-1, enhances the transcriptional response to Interferon-β of the OAS1 anti-viral gene.

Larsen S, Kawamoto S, Tanuma S, Uchiumi F.

Sci Rep. 2015 Dec 8;5:17497. doi: 10.1038/srep17497.

11.

Instructive roles for cytokine-receptor binding parameters in determining signaling and functional potency.

Moraga I, Richter D, Wilmes S, Winkelmann H, Jude K, Thomas C, Suhoski MM, Engleman EG, Piehler J, Garcia KC.

Sci Signal. 2015 Nov 10;8(402):ra114. doi: 10.1126/scisignal.aab2677.

12.

Differences of IL-1β Receptors Expression by Immunocompetent Cells Subsets in Rheumatoid Arthritis.

Alshevskaya AA, Lopatnikova JA, Shkaruba NS, Chumasova OA, Sizikov AE, Karaulov AV, Kozlov VA, Sennikov SV.

Mediators Inflamm. 2015;2015:948393. doi: 10.1155/2015/948393. Epub 2015 Sep 10.

13.

Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling.

Wilmes S, Beutel O, Li Z, Francois-Newton V, Richter CP, Janning D, Kroll C, Hanhart P, Hötte K, You C, Uzé G, Pellegrini S, Piehler J.

J Cell Biol. 2015 May 25;209(4):579-93. doi: 10.1083/jcb.201412049.

14.

Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Westcott MM, Liu J, Rajani K, D'Agostino R Jr, Lyles DS, Porosnicu M.

J Virol. 2015 Aug;89(15):7944-54. doi: 10.1128/JVI.00757-15. Epub 2015 May 20.

15.

Interferons and viruses: an evolutionary arms race of molecular interactions.

Hoffmann HH, Schneider WM, Rice CM.

Trends Immunol. 2015 Mar;36(3):124-38. doi: 10.1016/j.it.2015.01.004. Epub 2015 Feb 20. Review.

16.

Interferon induction by RNA viruses and antagonism by viral pathogens.

Nan Y, Nan G, Zhang YJ.

Viruses. 2014 Dec 12;6(12):4999-5027. doi: 10.3390/v6124999. Review.

17.

Insights into cytokine-receptor interactions from cytokine engineering.

Spangler JB, Moraga I, Mendoza JL, Garcia KC.

Annu Rev Immunol. 2015;33:139-67. doi: 10.1146/annurev-immunol-032713-120211. Epub 2014 Dec 10. Review.

18.

Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types.

Tomasello E, Pollet E, Vu Manh TP, Uzé G, Dalod M.

Front Immunol. 2014 Oct 30;5:526. doi: 10.3389/fimmu.2014.00526. eCollection 2014. Review.

19.

How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.

Reder AT, Feng X.

J Interferon Cytokine Res. 2014 Aug;34(8):589-99. doi: 10.1089/jir.2013.0158. Review.

20.

Relationship between interleukin-1 type 1 and 2 receptor gene polymorphisms and the expression level of membrane-bound receptors.

Vasilyev FF, Silkov AN, Sennikov SV.

Cell Mol Immunol. 2015 Mar;12(2):222-30. doi: 10.1038/cmi.2014.43. Epub 2014 Jun 30.

Supplemental Content

Support Center